Glucosamine + Chondroitin

Verify with FDA CVM →

424 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
424
Total Reports
25
Deaths Reported
590.0%
Death Rate

Active Ingredients

Glucosamine + Chondroitin

Administration Routes

OralUnknownAuricular (Otic)

Species Affected

Dog 394
Cat 28
Human 2

Most Affected Breeds

Retriever - Labrador 75
Retriever - Golden 30
Crossbred Canine/dog 25
Domestic Shorthair 18
Shepherd Dog - German 12
Shepherd Dog - Australian 11
Pit Bull 10
Boxer (German Boxer) 9
Terrier - Yorkshire 9
Rottweiler 9

Most Reported Reactions

Emesis 89
Vomiting 78
Lethargy (see also Central nervous system depression in 'Neurological') 65
Diarrhoea 35
Lack of efficacy - NOS 32
Other abnormal test result NOS 26
Behavioural disorder NOS 23
Anorexia 21
Weight loss 19
Seizure NOS 17
Not eating 17
Decreased appetite 17

Outcome Breakdown

Recovered/Normal
182 (42.9%)
Outcome Unknown
105 (24.8%)
Ongoing
79 (18.6%)
Recovered with Sequela
33 (7.8%)
Euthanized
16 (3.8%)
Died
9 (2.1%)

Data Summary

Metric Value
Total adverse event reports 424
Reports involving death 25
Case-fatality rate (reported events) 590.0%
Distinct species in reports 3
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Glucosamine + Chondroitin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 424 adverse event reports referencing Glucosamine + Chondroitin, including 25 reports in which the animal died — a 590.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Glucosamine + Chondroitin. Reported administration routes include Oral, Unknown, Auricular (Otic). These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Glucosamine + Chondroitin reports are Dog (394 reports), Cat (28 reports), Human (2 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (75), Retriever - Golden (30), Crossbred Canine/dog (25) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Glucosamine + Chondroitin are Emesis (89), Vomiting (78), Lethargy (see also Central nervous system depression in 'Neurological') (65), Diarrhoea (35). Of the 424 reports with a coded outcome, Recovered/Normal is the leading category at 42.9%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Glucosamine + Chondroitin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial